Completed PHASE1 INTERVENTIONAL 2-arm NCT04420871

Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer

Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer Under Fed Conditions: a Multicenter, Randomized, Open-label, Three-period, and Reference-replicated Crossover Study

Sponsor: The Affiliated Hospital of Qingdao University

Conditions Patient Participation

Interventions 150 mg of Xeloda® 150 mg of capecitabine

Updated 4 times since 2020 Last updated: Jun 4, 2020 Started: Dec 10, 2018 Primary completion: Dec 28, 2018 Completion: Jan 26, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04420871, this PHASE1 trial focuses on Patient Participation and remains completed. Sponsored by The Affiliated Hospital of Qingdao University, it has been updated 4 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2020 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Affiliated Hospital of Qingdao University

Data source: The Affiliated Hospital of Qingdao University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Qingdao, China